Phase II clinical trial with long-term infusion of anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 (IL2) in patients with high risk neuroblastoma.

被引：0
|
作者：
Lode, Holger N.
Valteau-Couanet, Dominique
Troschke-Meurer, Sascha
Manzitti, Carla
Gray, Juliet
Castel, Victoria
Yaniv, Isaac
Loibner, Hans
Siebert, Nikolai
Glogova, Evgenia
Poetschger, Ulrike
Ladenstein, Ruth
机构：
[1] Univ Med Greifswald, Greifswald, Germany
[2] Univ Paris Sud, Inst Gustave Roussy, Pediat & Adolescent Oncol, Villejuif, France
[3] Gaslini Inst, Genoa, Italy
[4] Univ Southampton, Southampten, England
[5] Pediat Oncol Unit Hosp La Fe Valencia, Pediat Hematol & Oncol, Valencia, Spain
[6] Schneider Childrens Med Ctr Israel, Pediat Hematol Oncol, Petah Tiqwa, Israel
[7] Apeiron Biol AG, Vienna, Austria
[8] St Anna Kinderkrebsforschung eV, Vienna, Austria
[9] St Anna Childrens Canc Res Inst, Vienna, Austria
[10] St Anna Childrens Hosp & Res Inst, Paediat Haematol Oncol, SIOP Europe Neuroblastoma Grp, Vienna, Austria
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.10562
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10562
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Effect of PD1/PD-L1 checkpoint blockade on efficacy of anti-GD2 antibody ch14.18/CHO in neuroblastoma.
    Lode, Holger N.
    Zumpe, Maxi
    Juettner, Madlen
    Troschke-Meurer, Sascha
    Loibner, Hans
    Siebert, Nikolai
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [22] Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma.
    Yu, Alice L.
    Gilman, Andrew L.
    Ozkaynak, M. Fevzi
    London, Wendy B.
    Kreissman, Susan G.
    Chen, Helen X.
    Smith, Malcolm
    Anderson, Barry
    Villablanca, Judith G.
    Matthay, Katherine K.
    Shimada, Hiro
    Grupp, Stephan A.
    Seeger, Robert
    Reynolds, C. Patrick
    Buxton, Allen
    Reisfeld, Ralph A.
    Gillies, Steven D.
    Cohn, Susan L.
    Maris, John M.
    Sondel, Paul M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (14): : 1324 - 1334
  • [23] Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial
    Siebert, Nikolai
    Troschke-Meurer, Sascha
    Marx, Madlen
    Zumpe, Maxi
    Ehlert, Karoline
    Gray, Juliet
    Garaventa, Alberto
    Manzitti, Carla
    Ash, Shifra
    Klingebiel, Thomas
    Beck, James
    Castel, Victoria
    Valteau-Couanet, Dominique
    Loibner, Hans
    Ladenstein, Ruth
    Lode, Holger N.
    CANCERS, 2018, 10 (10):
  • [24] Immunological long-term follow-up of neuroblastoma stage IV patients after anti-GD2 CH14.18 antibody treatment.
    Kayser, Simone
    Icheva, Vanya
    Stevanovic, Stefan
    Siebert, Nikolai
    Feucht, Judith
    Lode, Holger N.
    Handgretinger, Rupert
    Feuchtinger, Tobias
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [25] Pharmacokinetics of human-mouse chimeric anti-GD2 mAb ch14.18 in a phase I trial in neuroblastoma patients
    UttenreutherFischer, MM
    Huang, CS
    Yu, AL
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 1995, 41 (06) : 331 - 338
  • [26] Vaccination of high-risk neuroblastoma patients with anti-id antibody ganglidiomab to maintain protective immunity after passive immunotherapy with anti-GD2 antibody ch14.18/CHO
    Loibner, Hans
    Lode, Holger
    Siebert, Nikolai
    Troschke-Meurer, Sascha
    Mutschlechner, Oliver
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [27] PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD2 antibody ch14.18/CHO
    Siebert, Nikolai
    Zumpe, Maxi
    Juettner, Madlen
    Troschke-Meurer, Sascha
    Lode, Holger N.
    ONCOIMMUNOLOGY, 2017, 6 (10):
  • [28] Survival of Neuroblastoma Patients Treated by Long-Term Infusion of Anti-GD2 Antibody CH14.18/CHO Correlate with Killer-Cell Ig-Like Receptor (KIR) Genotypes and Fcγ-Receptor Polymorphisms
    Lode, H.
    Troschke-Meurer, S.
    Valteau-Couanet, D.
    Garaventa, A.
    Gray, J.
    Castel, V.
    Yaniv, I.
    Siebert, N.
    Eger, C.
    Juettner, M.
    Kietz, S.
    Karoline, E.
    Janzek, E.
    Loibner, H.
    Mueller, I.
    Ladenstein, R.
    PEDIATRIC BLOOD & CANCER, 2016, 63 : S39 - S39
  • [29] Survival of neuroblastoma patients treated by long-term infusion of anti-GD2 antibody ch14.18/CHO and killer-cell Ig-like receptor (KIR) genotypes and Fcγ-receptor polymorphisms.
    Lode, Holger N.
    Loibner, Hans
    Troschke-Meurer, Sascha
    Couanet, Dominique Valteau
    Garaventa, Alberto
    Gray, Juliet
    Castel, Victoria
    Yaniv, Isaac
    Siebert, Nikolai
    Eger, Christin
    Juettner, Madlen
    Kietz, Silke
    Ehlert, Karoline
    Janzek, Evelyne
    Mueller, Ina
    Ladenstein, Ruth
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (07)
  • [30] COMBINATION MORPHINE AND KETAMINE IN HIGH RISK NEUROBLASTOMA PATIENTS RECEIVING CH14.18/CHO ANTIBODY/IL2 MAXIMISES ANALGESIA, MINIMISES SIDE EFFECTS AND OPTIMISES IMMUNOTHERAPY DELIVERY
    Patton, G.
    Reilly, C.
    Canning, M.
    Cupples, P.
    Moores, T.
    Bell, G.
    Ronghe, M.
    Sastry, J.
    Murphy, D.
    PEDIATRIC BLOOD & CANCER, 2014, 61 : S218 - S218
12345